%0 Journal Article %T Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy %+ Institut Cochin (IC UM3 (UMR 8104 / U1016)) %+ Département d'hépatologie %+ Immunobiologie des Cellules Dendritiques %+ Epidémiologie, systèmes d'information, modélisation %+ Departement d'Hépatho-Gastro-Enterologie [Mondor] %+ Centre d'Immunologie Humaine (CIH) %+ Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy) %+ Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE) %+ CHU Saint-Antoine [AP-HP] %+ Immunité et Infection %+ Imagine - Institut des maladies génétiques (IMAGINE - U1163) %+ Laboratory of Human Genetics of Infectious Diseases %+ Biomarqueurs CArdioNeuroVASCulaires (BioCANVAS) %+ Department of anesthesiology and critical care medicine %+ Département Infection et Epidémiologie - Department of Infection and Epidemiology %A Sultanik, Philippe %A Mallet, Vincent %A Lagaye, Sylvie %A Casrouge, Armanda %A Dorival, Céline %A Barthe, Yoann %A Fontaine, Hélène %A Hézode, Christophe %A Mottez, Estelle %A Bronowicki, Jean-Pierre %A Carrat, Fabrice %A Theodorou, Ioannis %A Abel, Laurent %A Gayat, Etienne %A Fontanet, Arnaud %A Pol, Stanislas %A Albert, Matthew L. %Z The CUPIC Cohort study was sponsored and funded by The National Agency for research on Aids and Viral Hepatitis (ANRS), with support by the French Association for the Study of the Liver(AFEF). The authors also wish to acknowledge the Center for Human Immunology for its support of the research project. %< avec comité de lecture %@ 1478-3223 %J Liver International %I Wiley-Blackwell %V 35 %N 7 %P 1833 - 1844 %8 2015-07-30 %D 2015 %R 10.1111/liv.12759 %M 25556540 %K HCV protease inhibitor %K apolipoprotein H %K biomarker %K chronic hepatitis C %K virological response %Z Life Sciences [q-bio]/ImmunologyJournal articles %X BACKGROUND & AIMS:Chronic infection with HCV remains a public health problem with approximately 150 million people infected worldwide. HCV intersects with lipid metabolism for replication and entry; and plasma concentrations of apolipoproteins have been identified as predictors for response to therapy. Herein, we conducted a screen of plasma proteins, including all apolipoproteins, to identify correlates of response to pegylated-interferon/ribavirin (PR) and HCV non-structural protein 3 (NS3) inhibitors (i.e., telaprevir/boceprevir) therapy in treatment-experienced cirrhotic patients from the ANRS CUPIC cohort.METHODS:We analysed 220 baseline plasma protein concentrations in 189 patients using Luminex technology and analyzed results.RESULTS:We identified baseline levels of apolipoprotein H (apoH) as a surrogate marker for sustained virological response (SVR). Notably, increased plasma concentration of apoH, used in combination with known clinical parameters, established a robust model with improved classification of patients as likely to achieve SVR (AUC = 0.77, Se = 66%, Sp = 72%, NRI = 39%). Moreover, we provide mechanistic information that indicates a previously unidentified role for apoH during viral entry. Using a human liver slices HCV infection model, we demonstrate that apoH limits replication.CONCLUSION:These data support testing of new biomarker strategies for the management of cirrhotic HCV patients and expand our understanding of how apoH may intersect with HCV infection %G English %L pasteur-01380846 %U https://pasteur.hal.science/pasteur-01380846 %~ PASTEUR %~ UNIV-PARIS5 %~ UNIV-PARIS7 %~ UNIV-PARIS13 %~ UPMC %~ CNRS %~ APHP %~ ATP-IMMUN %~ UNIV-LORRAINE %~ NGERE-UL %~ SORBONNE-UNIVERSITE %~ SU-INF-2018 %~ SU-MEDECINE %~ SU-MED %~ SORBONNE-PARIS-NORD %~ UNIV-PARIS %~ UP-SANTE %~ BMS-UL %~ ALLIANCE-SU